for preoperative chemotherapy have been found to be related to poor prognosis in gastric cancer people, CT scan is an important method for preoperative evaluation. But the overall accuracy is from 43% to 82%, 6 and to find predictors of curative effect for neoadjuvant chemotherapy for T staging is necessary.
Immune cells are closely associated with tumorigenesis. They play a critical role in almost every stage of cancer development. 7 Several reports have suggested that elevated inflammatory markers such as platelet/lymphocyte ratio (PLR) and neutrophil/lymphocyte ratio (NLR), in patients with different types of malignancies, were associated with a poor prognosis. [8] [9] [10] [11] [12] Evidence for these biomarkers as direct predictors of result in advanced gastric cancer patients who received neoadjuvant chemotherapy is limited. Therefore, we conducted this research to evaluate the association NLR and PLR levels with the clinical outcome of neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Furthermore, the changes in these biomarkers after NAC were also assessed to discuss their value as potentially useful predictors.
| MATERIALS AND METHODS

| Patients
A total of 111 gastric cancer patients (stage T3 or T4 and nodepositive) who received preoperative NAC followed by D2 gastrectomy in the Shandong cancer hospital affiliated to Shandong University between 2007 and 2015 were evaluated retrospectively.
Before preoperative NAC, gastric adenocarcinoma was histologically confirmed in all patients. The exclusive criteria were as follows:
(i) The patients died of other diseases; (ii) the patients had autoimmune diseases; (iii) the patients were found to have other tumors; (iv) the patients with distant metastases did not do R0 resection; a total of 91 normal volunteers (NVs) were also recruited in this research.
Written informed consent was obtained from all people. All NVs un- 
| Chemotherapy regimen
Gastric cancer patients were treated with NAC every 2 weeks, and the regimens were as follows: DOF scheme (docetaxel 50 mg/m ). All patients were routinely examined by CT during the period of NAC, and NAC efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1. 13 Based on the clinical reaction, the patients were separated into non-responder group (PD) and responder group (CR, PR, and SD). Patients were followed up until death or until the cutoff date of May 2016. The median follow-up interval was 22 months (from 8 to 67 months). Finally, a total of 91 patients were eligible in this research.
91 patients were divided into patients who received DOF regimens ("Docetaxel, oxaliplatin and fluo" group) and patients who received FOLFOX or DF regimens ("Other, fluorouracil" group). There was no statistically significant difference between the two groups regarding either median OS (25 vs 27 months; P = .275; Figure 1C ). 
| Blood sample analysis
| Tumor regression score
The degree of tumor regression was recorded based on NCCN guidelines version 2.2016 gastric cancer. 14 
| Statistical analysis
The SPSS 22.0 software (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. A value of P < .05 was regarded as significantly different.
Count data were analyzed by chi-square test. Measurement data were expressed as the mean ± standard deviation (SD) and analyzed by t test.
The Kaplan-Meier method was used to analyze the five-year survival rate. The log-rank was employed in univariate survival analysis.
| RESULTS
| Patient characteristics
In total, 91 normal volunteers (NVs) were recruited, with the GC group presenting similar gender and age proportion as the NV group (both P > .05, Figure 1A and B). Compared with GC patients, PLR and NLR were significantly lower in NVs (P < .05, Figure 2 ). The characteristics of the 91 GC patients are shown in T A B L E 1 (Continued)
The blood PLR and NLR in patients with GC were significantly higher than those in NVs (127.8 ± 63.5 vs 110.9 ± 23.5; 1.85 ± 0.08, 1.62 ± 0.06; P < .05) Table 2 ).
The results demonstrated that aft-NAC NLR and aft-NAC PLR did
not show any significant difference in age, gender, response evaluation, tumor location, pathological type, pathological type, primary tumor (T), regional lymph nodes (N), neural invasion, lymphatic-vascular invasion, tumor stage. Moreover, we found that the low aft-NAC NLR patients had the higher rate of tumor regression than the patients with high aft-NAC NLR (P = .015) after neoadjuvant chemotherapy but before surgery ( Table 3 ). The univariate analyses showed that pre-NAC PLR low patients had better OS (P < .05; Table 4 ). Worse OS was seen in high pre-NAC PLR patients than those with low pre-NAC PLR. (median OS 15 months vs 33 months; P < .05).The multivariate Cox proportional hazard regression analysis indicated that pre-PLR was an independent prognostic factor (HR = 0.353, 95% CI: 0.162-0.769, P < 0.05) ( Table 5 ). Figure 4 ).
| PLR variation correlation with OS
| DISCUSSION
Gastric cancer is usually diagnosed at a locally advanced stage.
Multimodal therapy, including perioperative chemotherapy, targeted therapy, and radiotherapy, has greatly improved the survival of T In the last decade, more and more studies have reported that the systemic inflammatory response is closely related to a poor outcome in many types of tumor. [17] [18] [19] [20] [21] [22] The accumulating increase in NLR and PLR may be caused by peritumoral inflammation produced by a huge amount of cancer cells in patients with advanced cancer. Many studies demonstrate that PLR and NLR are useful biomarkers to predict prognostic outcome in unresectable gastric cancer, resectable gastric cancer, or gastric cancer patients who received chemotherapy. [23] [24] [25] However, whether they were associated with locally advanced gastric cancer patients treated with NAC followed by radical gastrectomy is rarely reported.
Our study showed that high pre-NAC PLR was significantly worse for OS than that in the low group in locally advanced gastric cancer patients who received NAC followed by gastrectomy (P < .05 Furthermore, we also found that PLR level variation after NAC predicted OS. But pre-NAC NLR, aft-NAC PLR, and aft-NAC NLR lost its meaning as a independently prognostic factor.
| CONCLUSIONS
Pre-NAC PLR could be an easily measured, convenient prognostic indicator for locally advanced gastric cancer patients treated with NAC.
Patients with high pre-NAC PLR values need multimodal therapy. Aft-NAC PLR level was negatively correlated with survival prognosis. Aft-NAC NLR level may help clinicians to find those patients with gastric cancer who will benefit from NAC, and aft-NAC PLR level variation may represent prognostic indicator.
The major limitations of our research were a retrospective study and insufficient number of patients. However, we found that measurement of pre-NAC PLR using a quick, low-cost, and easy test based on peripheral blood count can be used as a clinical marker and predict prognosis in gastric cancer patients. Aft-NAC PLR level variation may represent prognostic indicator in patients with NAC gastric cancer.
(The literature available data in this field is limited). But our findings will need to be confirmed with randomized, prospective, larger studies.
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